Evidence map›Paper›PMID 38913762›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee.

Ethan D Borre, Aima A Ahonkhai, Kyu-Young Kevin Chi, Amna Osman, Krista Thayer, Anna K Person, Andrea Weddle, Clare F Flanagan, April C Pettit, David Closs and 9 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Clinical Consequences of Delaying Implementation of Long-Acting Antiretroviral Therapy for People With HIV and Persistent Viremia in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ethan D BorreMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-8666-5382
Aima A AhonkhaiDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kyu-Young Kevin ChiMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Amna OsmanNashville CARES, Nashville, Tennessee, USA.
Krista ThayerFriends For All, Memphis, Tennessee, USA.
Anna K PersonDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Andrea WeddleHIV Medicine Association of the Infectious Diseases Society of America, Arlington, Virginia, USA.
Clare F FlanaganMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
April C PettitDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0001-8832-0866
David ClossFriends For All, Memphis, Tennessee, USA.
Mia CottonFriends For All, Memphis, Tennessee, USA.
Allison L AgwuDivision of Pediatric Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-8449-222X
Michelle S CespedesDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Andrea L CiaranelloMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Gregg GonsalvesPublic Health Modeling Unit and Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA.ORCID 0000-0002-5789-9841
Emily P HyleMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
A David PaltielPublic Health Modeling Unit and Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA.
Kenneth A FreedbergMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Anne M NeilanMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-7915-4974

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
SDMC; Statistical Data Mgmt CoreUM2HD111102 · NICHD · FLORIDA STATE UNIVERSITY · PI Lisa B Hightow-Weidman, Sybil Hosek · 2023 to 2026
$49.7M
Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Stephany Norah Duda · 2015 to 2026
$27.5M
Development and application of a new simulation model for COVID-19R01AI042006 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Anne Neilan · 1998 to 2026
$12.9M
Medical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6M
Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR37DA015612 · NIDA · STANFORD UNIVERSITY · PI DOUGLAS K OWENS · 2019 to 2026
$6.3M
Technology Based Community Health Nursing to Improve cART Adherence and Virologic Suppression in Youth Living with HIV (TechN 2 CheckIN): A Regional Multi-site StudyR01MD011770 · NIMHD · JOHNS HOPKINS UNIVERSITY · PI AGWU, ALLISON L, TRENT, MARIA E. · 2017 to 2021
$4.0M
Novel, Adaptive Approaches to Predicting and Responding to Outbreaks of Overdose, HIV and HCV Among People Who Use DrugsDP2DA049282 · NIDA · YALE UNIVERSITY · PI GONSALVES, GREGG STEVEN · 2019 to 2019
$2.5M
Strategies to Achieve Viral Suppression for Youth with HIV (The SAVVY Study)R01MH134724 · NIMH · JOHNS HOPKINS UNIVERSITY · PI ALLISON L AGWU · 2023 to 2026
$2.0M
Diagnosing and preventing HIV infection in adolescents and young adults in the US: clinical impact and cost-effectivenessK08HD094638 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI NEILAN, ANNE · 2018 to 2023
$936k
Eunice Kennedy Shriver National Institute for Child Health and Human Development K08 HD094638-05S1NCATS NIH HHS UL1 TR001863NIAID NIH HHS P30 AI094189NIAID NIH HHS P30 AI110527NIAID NIH HHS R01 AI042006NICHD NIH HHS K08 HD094638NICHD NIH HHS UM2 HD111102NIDA NIH HHS DP2 DA049282NIDA NIH HHS R37 DA015612NIGMS NIH HHS T32 GM145449NIH HHSNIMHD NIH HHS R01 MD011770NIMH NIH HHS R01 MH134724
6 · The paper itself

Abstract

backgroundIn 2023, Tennessee replaced $6.2 M in US Centers for Disease Control and Prevention (CDC) human immunodeficiency virus (HIV) prevention funding with state funds to redirect support away from men who have sex with men (MSM), transgender women (TGW), and heterosexual Black women (HSBW) and to prioritize instead first responders (FR), pregnant people (PP), and survivors of sex trafficking (SST).

methodsWe used a simulation model of HIV disease to compare the clinical impact of Current, the present allocation of condoms, preexposure prophylaxis (PrEP), and HIV testing to CDC priority risk groups (MSM/TGW/HSBW); with Reallocation, funding instead increased HIV testing and linkage of Tennessee-determined priority populations (FR/PP/SST). Key model inputs included baseline condom use (45%-49%), PrEP provision (0.1%-8%), HIV testing frequency (every 2.5-4.8 years), and 30-day HIV care linkage (57%-65%). We assumed Reallocation would reduce condom use (-4%), PrEP provision (-26%), and HIV testing (-47%) in MSM/TGW/HSBW, whereas it would increase HIV testing among FR (+47%) and HIV care linkage (to 100%/90%) among PP/SST.

resultsReallocation would lead to 166 additional HIV transmissions, 190 additional deaths, and 843 life-years lost over 10 years. HIV testing reductions were most influential in sensitivity analysis; even a 24% reduction would result in 287 more deaths compared to Current. With pessimistic assumptions, we projected 1359 additional HIV transmissions, 712 additional deaths, and 2778 life-years lost over 10 years.

conclusionsRedirecting HIV prevention funding in Tennessee would greatly harm CDC priority populations while conferring minimal benefits to new priority populations.

Indexed as

HIV InfectionsPre-Exposure ProphylaxisAdolescentAdultCenters for Disease Control and Prevention, U.S.CondomsCost-Benefit AnalysisFemaleHIV TestingHomosexuality, MaleHumansMaleMiddle AgedPregnancyTennesseeTransgender PersonsHealth policyHIVHIV preventionHIV prevention resource allocationTennessee HIV prevention

Identifiers

PMID38913762
PMCPMC11650892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.